News

"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin PhD, and Carl Danzig, MD had to say.

"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin, PhD, and Carl Danzig, MD had to say!

"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin PhD, and Carl Danzig, MD had to say!

Prevent Blindness plans to educate the public on the risk of significant eye injuries and the need for the proper sports eye protection, with more than 32,000 sports-related eye injuries treated in 2022, up almost 20 percent from previous year.

Researchers find gray GA lesions had the highest cross-modality differences

According to the university, a special antibody that is derived from llamas, called a nanobody, can stop the misfolding and the activation of Rhodopsin, a molecule whose mutations can lead to blindness.

According to the company, full enrollment anticipated by first week of September. The phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign and symptom of DED.

We asked, "What research at ASRS 2023 do you find exciting or interesting?" Here's what Paul Hahn, MD, PhD, Kerrie Brady, BPharm, MBA, MS, and Michael Singer, MD had to say!

Advancements from Carl Zeiss Medical AG in the cataract and cornea space include a new intraocular lens and therapeutic laser enhancements.

Maria H. Berrocal, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium in Marco Island, Florida.

The trial will be conducted by French tissue bank, TBF Génie Tissulaire.

According to the Keck School of Medicine of USC, the $12.4 million from the California Institute for Regenerative Medicine is the latest round of support for USC researcher Mark Humayun and a milestone in the development of a stem cell patch to treat advanced dry age-related macular degeneration.

The new platform incorporates the SILK procedure, allowing surgeons to perform refractive correction on patients with myopia.

The EUREQUO Annual Report celebrates 15 years and over 4 million surgical procedures in the registry.

In this podcast episode, Ophthalmology Times' co-chief medical editors Peter J. McDonnell, MD, and Neda Shamie, MD, delve into the clinical nuances of Demodex blepharitis. Through personal anecdotes, they stress its underrecognized gravity and discuss diagnostic cues like collarettes. The experts share their enthusiasm for improved treatments, echoing the transformative impact seen in dry eye care.

According to the company, it is working with the FDA to address the agency’s issues.

According to Outlook Therapeutics, it is working with the FDA to address the agency’s issues.

According to Outlook Therapeutics, it is working with the FDA to address the agency’s issues.

The study from New Zealand was conducted on an otherwise healthy 28-year-old woman.

Language can drive understanding, trust, and better outcomes for patients

Eva Kim, MD, spoke with our team to share insights from her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

According to the company, it is anticipating cost savings of up to $300 million through 2024, which includes an estimated 25% reduction in current workforce and a reduction in external expenses.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

OCT methods are invaluable in the assessment of patients with the condition

TOUR006 is an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED).

The organization says to stop using Dr. Berne’s and LightEyez MSM drops immediately due to bacterial contamination, fungal contamination, or both.